12
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Anagen Effluvium after Therapeutic Scalp Surgery: Unreported Phenomenon

      case-report

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: Many procedures are performed on the scalp, such as excision of pilar and sebaceous cysts, melanocytic nevi, and reduction surgery for scarring alopecia, among others. In hair transplants, telogen effluvium is often reported 3 months after surgery; however, hair loss usually happens much earlier, around second week after the procedure, not compatible with the time required for hair to enter telogen and exogenous phases in normal conditions. Case Reports: We report 3 cases of anagen hair loss 4 weeks after surgeries, with perilesional trichoscopy suggesting anagen effluvium, with typical signs such as black dots and exclamation hairs. Discussion: There are only a few reports about hair loss around operated areas. The cause of this postoperative anagen effluvium is probably a transient ischemia. Conclusion: The practical importance of this phenomenon is to properly orient patients because most of the hair will be lost, since 85% of them are anagens, and also will have spontaneous recovery in the next 3 months.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: not found
          • Article: not found

          Telogen effluvium : Telogen effluvium

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The surgical treatment of cicatricial alopecia.

            Surgical correction of cicatricial alopecia can yield exceptional results when performed in the appropriate clinical scenario. To facilitate determination of the most suitable corrective therapy, we propose two new categories of cicatricial alopecia: "unstable" and "stable." Unstable cicatricial alopecia is intermittent and results in possible subsequent scarring hair loss in either new or old areas. Stable cicatricial alopecia, on the other hand, refers to fixed permanent scarring. While surgical excision is preferred to hair transplantation for both categories of cicatricial alopecia, this preference is even stronger in cases of unstable cicatricial alopecia due to its intermittent and progressive nature. Regardless of which corrective technique is used, analysis of specific physical patient characteristics coupled with a careful view towards the possible evolution of male pattern baldness or female pattern hair loss are essential to achieve superior long-term results. Herein we also outline guidelines for identifying these physical traits as well as for performing hair transplantation and surgical excision in order to achieve optimal cosmetic outcomes and minimize postoperative complications.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Use of topical minoxidil as a possible adjunct to hair transplant surgery. A pilot study.

              J Kassimir (1987)
              Twelve patients, aged 21 to 60 years, with varying Hamilton classifications of androgenetic alopecia (male pattern baldness) were treated with a 3% solution of topical minoxidil. Therapy began 48 to 72 hours after hair transplant surgery. Two patients demonstrated hair growth in the grafts without the shedding that usually occurs 2 to 4 weeks after surgery. (In untreated patients after hair transplant surgery, regrowth begins 3 to 5 months after surgery, after the shedding period.) A review of the literature--and personal discussions with surgeons whose hair transplant experience spans 25 years--revealed no evidence of a similar report. In addition, two of the remaining 10 patients had regrowth less than 4 weeks after postsurgical telogen effluvium. Neither patient age nor number of grafts transplanted played a predictive role. The location of the operative procedure also failed to predict, or preclude, successful regrowth. Topical minoxidil may be an important adjunctive therapy during the recuperative period in patients who have undergone hair transplant surgery. Carefully controlled studies are needed to substantiate this preliminary observation.
                Bookmark

                Author and article information

                Journal
                SAD
                SAD
                10.1159/issn.2296-9160
                Skin Appendage Disorders
                S. Karger AG
                2296-9195
                2296-9160
                2021
                June 2021
                23 March 2021
                : 7
                : 4
                : 311-314
                Affiliations
                [_a] aDepartment of Dermatology, Hospital do Servidor Público Municipal de São Paulo, São Paulo, Brazil
                [_b] bDermatology, Hospital das Clínicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil
                Author notes
                *Vanessa Barreto Rocha, Dermatology, Hospital das Clínicas, Universidade Federal de Minas Gerais (UFMG), Ave. Contorno 9681 403 – Prado, Belo Horizonte 30110-063 (Brazil), vanessabarreto.vbr@gmail.com
                Author information
                https://orcid.org/0000-0001-6795-398X
                Article
                513087 Skin Appendage Disord 2021;7:311–314
                10.1159/000513087
                ce667ffe-77fb-48fb-92ca-24e1de2c267c
                © 2021 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 02 October 2020
                : 17 November 2020
                Page count
                Figures: 3, Pages: 4
                Categories
                Novel Insights from Clinical Practice

                Oncology & Radiotherapy,Pathology,Surgery,Dermatology,Pharmacology & Pharmaceutical medicine
                Scar,Alopecia,Scalp dermatosis,Hair disorders,Surgery

                Comments

                Comment on this article